Immunic (NASDAQ:IMUX) completed enrollment for its Phase 2 trial assessing IMU-838 for the treatment of relapsing-remitting multiple sclerosis (RRMS).
IMU-838 is a selective immune modulator that blocks the enzyme dihydroorotate dehydrogenase (DHODH).
The trial enrolled 210 patients in 36 centers across four European countries. The study will evaluate the dose response of 30 mg and 45 mg per day with a primary endpoint of the cumulative number of combined unique active MRI lesions up to week 24.
“Backed by newly-released preclinical data confirming the superior profile of IMU-838 versus the currently approved DHODH inhibitor, teriflunomide, we remain highly enthusiastic about the potential of IMU-838 to become an important new best-in-class oral therapeutic treatment alternative for patients with RRMS,” president and CEO Daniel Vitt said in a statement.
Immunic expects topline results to be available in the third quarter of 2020.
